These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35760803)
21. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway. Liang Z; Zhong Y; Meng L; Chen Y; Liu Y; Wu A; Li X; Wang M Thorac Cancer; 2020 Nov; 11(11):3155-3167. PubMed ID: 32926529 [TBL] [Abstract][Full Text] [Related]
22. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth. Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279 [TBL] [Abstract][Full Text] [Related]
23. Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway. Chen B; Song Y; Zhan Y; Zhou S; Ke J; Ao W; Zhang Y; Liang Q; He M; Li S; Xie F; Huang H; Chan WN; Cheung AHK; Ma BBY; Kang W; To KF; Xiao J Cancer Lett; 2022 Sep; 543():215783. PubMed ID: 35700820 [TBL] [Abstract][Full Text] [Related]
24. miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1. Zhang J; Li J; Li S; Zhou C; Qin Y; Li X Int J Oncol; 2019 Jun; 54(6):2211-2221. PubMed ID: 30942425 [TBL] [Abstract][Full Text] [Related]
25. Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. Berry GT; Wu S; Buccafusca R; Ren J; Gonzales LW; Ballard PL; Golden JA; Stevens MJ; Greer JJ J Biol Chem; 2003 May; 278(20):18297-302. PubMed ID: 12582158 [TBL] [Abstract][Full Text] [Related]
26. GDC-0349 inhibits non-small cell lung cancer cell growth. Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352 [TBL] [Abstract][Full Text] [Related]
27. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer. Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561 [TBL] [Abstract][Full Text] [Related]
28. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247 [TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000 [TBL] [Abstract][Full Text] [Related]
30. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway. Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489 [TBL] [Abstract][Full Text] [Related]
31. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
32. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway. Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326 [TBL] [Abstract][Full Text] [Related]
33. 2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells. Xie X; Zu X; Laster K; Dong Z; Kim DJ J Pharmacol Sci; 2021 Mar; 145(3):279-288. PubMed ID: 33602509 [TBL] [Abstract][Full Text] [Related]
34. An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling. Xu H; Sun H; Zhang H; Liu J; Fan F; Li Y; Ning X; Sun Y; Dai S; Liu B; Gao M; Fu S; Zhou C PLoS One; 2015; 10(5):e0124033. PubMed ID: 25962159 [TBL] [Abstract][Full Text] [Related]
35. Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer. Jiang JZ; Qiao YB; Zhu XR; Gu QH; Lu JJ; Ye ZY; Xu L; Liu YY Cell Death Dis; 2024 Sep; 15(9):699. PubMed ID: 39349432 [TBL] [Abstract][Full Text] [Related]
36. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth. Sun Y; Xie J; Cai S; Wang Q; Feng Z; Li Y; Lu JJ; Chen W; Ye Z Cell Death Dis; 2021 Oct; 12(10):913. PubMed ID: 34615858 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Lennon FE; Mirzapoiazova T; Mambetsariev B; Salgia R; Moss J; Singleton PA Anesthesiology; 2012 Apr; 116(4):857-67. PubMed ID: 22343475 [TBL] [Abstract][Full Text] [Related]
38. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Hu H; Wang F; Wang M; Liu Y; Wu H; Chen X; Lin Q Int J Med Sci; 2020; 17(6):807-814. PubMed ID: 32218702 [TBL] [Abstract][Full Text] [Related]
39. Gαi1/3 mediate Netrin-1-CD146-activated signaling and angiogenesis. Li Y; Chai JL; Shi X; Feng Y; Li JJ; Zhou LN; Cao C; Li KR Theranostics; 2023; 13(7):2319-2336. PubMed ID: 37153740 [TBL] [Abstract][Full Text] [Related]
40. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]